PRIVIA HEALTH GROUP INC (PRVA) Stock Analyst Ratings
USA - NASDAQ:PRVA - US74276R1023 - Common Stock
24.51 USD
-1.09 (-4.26%)
24.59 USD
+0.08 (+0.33%)
ChartMill assigns a Buy % Consensus number of 84% to PRVA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 31.19. This target is 27.26% above the current price.
PRVA was analyzed by 27 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about PRVA.
In the previous month the buy percentage consensus was at a similar level.
PRVA was analyzed by 27 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-09 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-09-24 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-09-04 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-08-29 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-08-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-09 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-05-28 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-27 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-28 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-04-15 | Baird | Maintains | Outperform -> Outperform |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-04-10 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2025-04-10 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-21 | Needham | Reiterate | Buy -> Buy |
| 2025-02-28 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-02-28 | Needham | Maintains | Buy -> Buy |
| 2025-02-28 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-02-28 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-02-14 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-01-15 | Needham | Reiterate | Buy -> Buy |
| 2025-01-10 | Needham | Initiate | Buy |
| 2025-01-07 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-01-02 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2024-12-16 | Macquarie | Initiate | Outperform |
| 2024-11-29 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-11-08 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-08 | Truist Securities | Maintains | Buy -> Buy |
| 2024-10-11 | Keybanc | Initiate | Overweight |
| 2024-08-26 | Baird | Maintains | Outperform -> Outperform |
| 2024-08-14 | RBC Capital | Reiterate | Outperform -> Outperform |
PRIVIA HEALTH GROUP INC / PRVA FAQ
Can you provide the average price target for PRIVIA HEALTH GROUP INC stock?
27 analysts have analysed PRVA and the average price target is 31.19 USD. This implies a price increase of 27.26% is expected in the next year compared to the current price of 24.51.
What is the consensus rating for PRVA stock?
The consensus rating for PRIVIA HEALTH GROUP INC (PRVA) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for PRVA stock?
The number of analysts covering PRIVIA HEALTH GROUP INC (PRVA) is 27.